Available long-term data on Fampyra (fampridine; 4-aminopyridine) suggest the treatment may improve walking speed in patients with multiple sclerosis (MS) for up to one year, but more research ... Read more
Atara Biotherapeutics has started a Phase 1 clinical trial to assess ATA188’s safety and potential to treat progressive or relapsing-remitting multiple sclerosis.
ATA188 is the company’s next-generation T-cell immunotherapy. ... Read more
British military personnel are at significantly higher risk of dying from multiple sclerosis than people in other occupations, a study reports.
University of Southampton researchers had done ... Read more
An Italian study recently found that Multiple sclerosis patients in the first year of diagnosis frequently suffer from depression, pre-morbid personality, self-perception issues and other psychological ... Read more
Patients with secondary progressive multiple sclerosis (SPMS) have a higher burden of illness than patients with relapsing-remitting multiple sclerosis, a new study showed. The study, “Characteristics, ... Read more
Pin It on Pinterest